Related Experiment Video
Updated: May 22, 2026
Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
Published on: November 17, 2023
Prognostic Significance of Pretreatment Blood-Based Biomarkers in Penile Cancer: A Multicenter Retrospective Study in
Shuichi Tatarano1, Makito Miyake2, Yu Osaki3
1Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Objectives:
Penile cancer is a rare malignancy, and multicenter data evaluating prognostic biomarkers in the Japanese population are limited. This study aimed to assess the prognostic significance of pretreatment blood-based biomarkers in patients with penile cancer.
Methods:
We conducted a multicenter retrospective cohort study including 111 patients with penile cancer treated between January 2005 and December 2023 at ten institutions participating in the West Japan Uro-oncology Collaboration Group. Cancer-specific survival (CSS) was analyzed using the Kaplan-Meier method and Cox proportional hazards model. Receiver operating characteristic analyses were performed to determine optimal cutoff values for the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and squamous cell carcinoma antigen (SCC-Ag). A composite biomarker score was calculated based on the number of elevated biomarkers.
Results:
The 5-year overall survival and CSS rates were 71.1% and 77.4%, respectively. In univariate analyses, elevated PLR, elevated SCC-Ag, and higher composite biomarker scores were significantly associated with poorer CSS. In multivariate analysis, advanced clinical nodal status (≥ cN2) and distant metastasis (cM1) remained independent predictors of CSS, whereas blood-based biomarkers did not retain independent prognostic significance after adjustment for established clinicopathological factors. Kaplan-Meier analyses demonstrated significantly worse CSS in patients with high PLR, high SCC-Ag levels, and higher composite biomarker scores.
Conclusions:
Pretreatment blood-based biomarkers, particularly PLR and SCC-Ag, are associated with prognosis in penile cancer. Although they did not retain independent prognostic factors after adjustment, these biomarkers may provide complementary prognostic information and help identify high-risk patients in clinical practice.
